3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
69
Triple Negative Breast Neoplasms
32
Ovarian Neoplasms
21
Neoplasm Metastasis
10
Prostatic Neoplasms
8
Pancreatic Neoplasms
7
Fanconi Anemia, Complementation Group D1
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Advanced Breast Cancer
4
Recurrence
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Small Cell Lung Carcinoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Inflammatory Breast Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Triple Negative Metastatic Breast Cancer
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Sarcoma
1
Radiation Injuries
1
Prostatic Neoplasms, Castration-Resistant
1
Primary Myelofibrosis
1
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian
1
Interventions
Trastuzumab
18
Radiosurgery
15
Capecitabine
13
Lapatinib
11
Radiotherapy
9
Magnetic Resonance Spectroscopy
9
trastuzumab deruxtecan
7
Temozolomide
6
tucatinib
4
pembrolizumab
4
paclitaxel-Angiopep-2 conjugate
4
eribulin
4
Vinorelbine
4
Specimen Handling
4
Paclitaxel
4
Methotrexate
4
Cisplatin
4
sacituzumab govitecan
3
pyrotinib
3
abemaciclib
3
Radiation
3
Fluorodeoxyglucose F18
3
pertuzumab
2
palbociclib
2
neratinib
2
durvalumab
2
cediranib
2
cabazitaxel
2
Sodium Chloride
2
Observation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Brain Neoplasms
×
olaparib
×
Breast
×
Clear all
NCT04711824
2025-12-23
SOLARA
Hoosier Cancer Research Network
Phase 1/2
Recruiting
41 enrolled